Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • Scientists Finish the Human Genome at Last https://t.co/bTRwmNjHwP
    about 10 hours ago
  • While the public's attention for the past 18 months has been focused on Covid-19, the problem of opioid overdoses a… https://t.co/gr0q6FkShP
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Drug Overdose Epidemic Accelerating https://t.co/rZP0zmFVgK #Science #Business
    about 1 day ago
  • "Unvaccinated people aren’t a random group of defectors who are trying to be deviant." @edyong209 talks to Dr. Rhea… https://t.co/FkzZWK83OE
    about 1 day ago
  • U.S. drops cases against five researchers accused of hiding ties to Chinese military https://t.co/0D4YvwvjZq
    about 2 days ago

Please share Science & Enterprise

Bayer Gains Gene Therapy Biotech in $4B Deal

AskBio Bioreactor

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Lilly Gains Neuro Disease Biotech in $1.36B Deal

Nerve cells illustration

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Heart Disease Biotech Acquired in $13.1B Deal

Wall Street sign

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Cancer Screening Analytics Company Acquired in $8B Deal

Blood sample vials

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Food Allergy Biotech Acquired for $2.6B

Palforzia capsules

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Human B-cell

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Infographic – Apple Leads in A.I. Acquistions

A.I. acquisitions chart

Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the past 10 years. . . . → Read More: Infographic – Apple Leads in A.I. Acquistions

Merck Inks Three Covid-19 Vaccine, Therapy Deals

SARS-Cov-2 virus

Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections. . . . → Read More: Merck Inks Three Covid-19 Vaccine, Therapy Deals

Synthetic Bio Cancer Immunotherapy Company Acquired

Natural killer cell

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired